Biogen Idec. Inc. has halted development of an experimental drug to treat the devastating neurodegenerative disorder known as Lou Gehrig’s disease, saying Thursday that it proved ineffective in a late-stage clinical trial.
The decision deals a blow to an estimated 30,000 Americans who suffer from amyotrophic lateral sclerosis, or ALS, a fatal condition for which there is no cure.
Comments
Any day now, we can expect to see an ad on tv with an 800 number saying, "If you were a patient involved in a clinical trial of dexpramidipexole, you may be entitled to compensation...." . The deep pockets of Biogen will be too much for the ambulance-chasers to resist.